id	sid	tid	token	lemma	pos
dpc-2847	1	1	dermatology	dermatology	NOUN
dpc-2847	1	2	:	:	PUNCT
dpc-2847	1	3	practical	practical	ADJ
dpc-2847	1	4	and	and	CCONJ
dpc-2847	1	5	conceptual	conceptual	ADJ
dpc-2847	1	6	research	research	NOUN
dpc-2847	1	7	letter	letter	NOUN
dpc-2847	2	1	|	|	ADV
dpc-2847	2	2	dermatol	dermatol	ADJ
dpc-2847	2	3	pract	pract	NOUN
dpc-2847	2	4	concept	concept	NOUN
dpc-2847	2	5	.	.	PUNCT
dpc-2847	3	1	2023;13(2):e2023130	2023;13(2):e2023130	NUM
dpc-2847	3	2	1	1	NUM
dpc-2847	3	3	sorafenib	sorafenib	NOUN
dpc-2847	3	4	-	-	PUNCT
dpc-2847	3	5	induced	induce	VERB
dpc-2847	3	6	acute	acute	NOUN
dpc-2847	3	7	generalized	generalize	VERB
dpc-2847	3	8	exanthematous	exanthematous	ADJ
dpc-2847	3	9	pustulosis	pustulosis	NOUN
dpc-2847	3	10	andrea	andrea	PROPN
dpc-2847	3	11	cortese1,2	cortese1,2	PROPN
dpc-2847	3	12	,	,	PUNCT
dpc-2847	3	13	saverio	saverio	PROPN
dpc-2847	3	14	pancetti3	pancetti3	PROPN
dpc-2847	3	15	,	,	PUNCT
dpc-2847	3	16	tiziana	tiziana	NOUN
dpc-2847	3	17	pressiani4	pressiani4	PROPN
dpc-2847	3	18	,	,	PUNCT
dpc-2847	3	19	francesco	francesco	PROPN
dpc-2847	3	20	toso1,2	toso1,2	PROPN
dpc-2847	3	21	,	,	PUNCT
dpc-2847	3	22	giovanni	giovanni	PROPN
dpc-2847	3	23	fiorillo1,2	fiorillo1,2	PROPN
dpc-2847	3	24	,	,	PUNCT
dpc-2847	3	25	antonio	antonio	PROPN
dpc-2847	3	26	costanzo1,2	costanzo1,2	PROPN
dpc-2847	3	27	,	,	PUNCT
dpc-2847	3	28	riccardo	riccardo	PROPN
dpc-2847	3	29	giovanni	giovanni	PROPN
dpc-2847	3	30	borroni1,2	borroni1,2	PROPN
dpc-2847	3	31	1	1	NUM
dpc-2847	3	32	dermatology	dermatology	NOUN
dpc-2847	3	33	,	,	PUNCT
dpc-2847	3	34	humanitas	humanita	NOUN
dpc-2847	3	35	research	research	NOUN
dpc-2847	3	36	hospital	hospital	NOUN
dpc-2847	3	37	–	–	PUNCT
dpc-2847	3	38	irccs	irccs	NOUN
dpc-2847	3	39	,	,	PUNCT
dpc-2847	3	40	rozzano	rozzano	X
dpc-2847	3	41	(	(	PUNCT
dpc-2847	3	42	mi	mi	PROPN
dpc-2847	3	43	)	)	PUNCT
dpc-2847	3	44	,	,	PUNCT
dpc-2847	3	45	italy	italy	PROPN
dpc-2847	3	46	2	2	NUM
dpc-2847	3	47	department	department	NOUN
dpc-2847	3	48	of	of	ADP
dpc-2847	3	49	biomedical	biomedical	ADJ
dpc-2847	3	50	sciences	sciences	PROPN
dpc-2847	3	51	,	,	PUNCT
dpc-2847	3	52	humanitas	humanita	NOUN
dpc-2847	3	53	university	university	NOUN
dpc-2847	3	54	,	,	PUNCT
dpc-2847	3	55	pieve	pieve	PROPN
dpc-2847	3	56	emanuele	emanuele	PROPN
dpc-2847	3	57	(	(	PUNCT
dpc-2847	3	58	mi	mi	PROPN
dpc-2847	3	59	)	)	PUNCT
dpc-2847	3	60	,	,	PUNCT
dpc-2847	3	61	italy	italy	PROPN
dpc-2847	3	62	3	3	NUM
dpc-2847	3	63	pathology	pathology	PROPN
dpc-2847	3	64	,	,	PUNCT
dpc-2847	3	65	humanitas	humanitas	PROPN
dpc-2847	3	66	research	research	NOUN
dpc-2847	3	67	hospital	hospital	NOUN
dpc-2847	3	68	irccs	irccs	NOUN
dpc-2847	3	69	,	,	PUNCT
dpc-2847	3	70	rozzano	rozzano	PROPN
dpc-2847	3	71	(	(	PUNCT
dpc-2847	3	72	mi	mi	PROPN
dpc-2847	3	73	)	)	PUNCT
dpc-2847	3	74	,	,	PUNCT
dpc-2847	3	75	italy	italy	PROPN
dpc-2847	3	76	4	4	NUM
dpc-2847	3	77	oncology	oncology	NOUN
dpc-2847	3	78	,	,	PUNCT
dpc-2847	3	79	humanitas	humanita	NOUN
dpc-2847	3	80	research	research	NOUN
dpc-2847	3	81	hospital	hospital	NOUN
dpc-2847	3	82	irccs	irccs	NOUN
dpc-2847	3	83	,	,	PUNCT
dpc-2847	3	84	rozzano	rozzano	PROPN
dpc-2847	3	85	(	(	PUNCT
dpc-2847	3	86	mi	mi	PROPN
dpc-2847	3	87	)	)	PUNCT
dpc-2847	3	88	,	,	PUNCT
dpc-2847	3	89	italy	italy	PROPN
dpc-2847	3	90	key	key	PROPN
dpc-2847	3	91	words	word	NOUN
dpc-2847	3	92	:	:	PUNCT
dpc-2847	3	93	sorafenib	sorafenib	NOUN
dpc-2847	3	94	,	,	PUNCT
dpc-2847	3	95	acute	acute	NOUN
dpc-2847	3	96	generalized	generalize	VERB
dpc-2847	3	97	exanthematous	exanthematous	ADJ
dpc-2847	3	98	pustulosis	pustulosis	NOUN
dpc-2847	3	99	,	,	PUNCT
dpc-2847	3	100	severe	severe	ADJ
dpc-2847	3	101	cutaneous	cutaneous	ADJ
dpc-2847	3	102	adverse	adverse	ADJ
dpc-2847	3	103	reaction	reaction	NOUN
dpc-2847	3	104	;	;	PUNCT
dpc-2847	3	105	tyrosin	tyrosin	NOUN
dpc-2847	3	106	-	-	PUNCT
dpc-2847	3	107	kinase	kinase	PROPN
dpc-2847	3	108	inhibitors	inhibitor	NOUN
dpc-2847	3	109	citation	citation	NOUN
dpc-2847	3	110	:	:	PUNCT
dpc-2847	3	111	cortese	cortese	PROPN
dpc-2847	3	112	a	a	X
dpc-2847	3	113	,	,	PUNCT
dpc-2847	3	114	pancetti	pancetti	PROPN
dpc-2847	3	115	s	s	PROPN
dpc-2847	3	116	,	,	PUNCT
dpc-2847	3	117	pressiani	pressiani	PROPN
dpc-2847	3	118	t	t	PROPN
dpc-2847	3	119	,	,	PUNCT
dpc-2847	3	120	et	et	PROPN
dpc-2847	3	121	al	al	PROPN
dpc-2847	3	122	.	.	PROPN
dpc-2847	3	123	sorafenib	sorafenib	PROPN
dpc-2847	3	124	-	-	PUNCT
dpc-2847	3	125	induced	induce	VERB
dpc-2847	3	126	acute	acute	NOUN
dpc-2847	3	127	generalized	generalize	VERB
dpc-2847	3	128	exanthematous	exanthematous	ADJ
dpc-2847	3	129	pustulosis	pustulosis	NOUN
dpc-2847	3	130	.	.	PUNCT
dpc-2847	4	1	dermatol	dermatol	NOUN
dpc-2847	4	2	pract	pract	PROPN
dpc-2847	4	3	concept	concept	NOUN
dpc-2847	4	4	.	.	PUNCT
dpc-2847	5	1	2023;13(2):e2023130	2023;13(2):e2023130	X
dpc-2847	5	2	.	.	PUNCT
dpc-2847	5	3	doi	doi	PROPN
dpc-2847	5	4	:	:	PUNCT
dpc-2847	5	5	https://doi.org/10.5826/dpc.1302a130	https://doi.org/10.5826/dpc.1302a130	PROPN
dpc-2847	5	6	accepted	accept	VERB
dpc-2847	5	7	:	:	PUNCT
dpc-2847	5	8	november	november	PROPN
dpc-2847	5	9	17	17	NUM
dpc-2847	5	10	,	,	PUNCT
dpc-2847	5	11	2022	2022	NUM
dpc-2847	5	12	;	;	PUNCT
dpc-2847	5	13	published	publish	VERB
dpc-2847	5	14	:	:	PUNCT
dpc-2847	6	1	april	april	PROPN
dpc-2847	6	2	2023	2023	NUM
dpc-2847	6	3	copyright	copyright	NOUN
dpc-2847	6	4	:	:	PUNCT
dpc-2847	6	5	©	©	PROPN
dpc-2847	6	6	2023	2023	NUM
dpc-2847	6	7	cortese	cortese	PROPN
dpc-2847	6	8	et	et	PROPN
dpc-2847	6	9	al	al	PROPN
dpc-2847	6	10	.	.	PUNCT
dpc-2847	7	1	this	this	PRON
dpc-2847	7	2	is	be	AUX
dpc-2847	7	3	an	an	DET
dpc-2847	7	4	open	open	ADJ
dpc-2847	7	5	-	-	PUNCT
dpc-2847	7	6	access	access	NOUN
dpc-2847	7	7	article	article	NOUN
dpc-2847	7	8	distributed	distribute	VERB
dpc-2847	7	9	under	under	ADP
dpc-2847	7	10	the	the	DET
dpc-2847	7	11	terms	term	NOUN
dpc-2847	7	12	of	of	ADP
dpc-2847	7	13	the	the	DET
dpc-2847	7	14	creative	creative	ADJ
dpc-2847	7	15	commons	common	NOUN
dpc-2847	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2847	7	17	license	license	NOUN
dpc-2847	7	18	(	(	PUNCT
dpc-2847	7	19	by	by	ADP
dpc-2847	7	20	-	-	PUNCT
dpc-2847	7	21	nc-4.0	nc-4.0	NOUN
dpc-2847	7	22	)	)	PUNCT
dpc-2847	7	23	,	,	PUNCT
dpc-2847	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2847	7	25	,	,	PUNCT
dpc-2847	7	26	which	which	PRON
dpc-2847	7	27	permits	permit	VERB
dpc-2847	7	28	unrestricted	unrestricted	ADJ
dpc-2847	7	29	noncommercial	noncommercial	ADJ
dpc-2847	7	30	use	use	NOUN
dpc-2847	7	31	,	,	PUNCT
dpc-2847	7	32	distribution	distribution	NOUN
dpc-2847	7	33	,	,	PUNCT
dpc-2847	7	34	and	and	CCONJ
dpc-2847	7	35	reproduction	reproduction	NOUN
dpc-2847	7	36	in	in	ADP
dpc-2847	7	37	any	any	DET
dpc-2847	7	38	medium	medium	NOUN
dpc-2847	7	39	,	,	PUNCT
dpc-2847	7	40	provided	provide	VERB
dpc-2847	7	41	the	the	DET
dpc-2847	7	42	original	original	ADJ
dpc-2847	7	43	authors	author	NOUN
dpc-2847	7	44	and	and	CCONJ
dpc-2847	7	45	source	source	NOUN
dpc-2847	7	46	are	be	AUX
dpc-2847	7	47	credited	credit	VERB
dpc-2847	7	48	.	.	PUNCT
dpc-2847	8	1	funding	funding	NOUN
dpc-2847	8	2	:	:	PUNCT
dpc-2847	8	3	none	none	NOUN
dpc-2847	8	4	.	.	PUNCT
dpc-2847	9	1	competing	compete	VERB
dpc-2847	9	2	interests	interest	NOUN
dpc-2847	9	3	:	:	PUNCT
dpc-2847	9	4	none	none	NOUN
dpc-2847	9	5	.	.	PUNCT
dpc-2847	10	1	authorship	authorship	NOUN
dpc-2847	10	2	:	:	PUNCT
dpc-2847	10	3	all	all	DET
dpc-2847	10	4	authors	author	NOUN
dpc-2847	10	5	have	have	AUX
dpc-2847	10	6	contributed	contribute	VERB
dpc-2847	10	7	significantly	significantly	ADV
dpc-2847	10	8	to	to	ADP
dpc-2847	10	9	this	this	DET
dpc-2847	10	10	publication	publication	NOUN
dpc-2847	10	11	.	.	PUNCT
dpc-2847	11	1	corresponding	correspond	VERB
dpc-2847	11	2	author	author	NOUN
dpc-2847	11	3	:	:	PUNCT
dpc-2847	11	4	andrea	andrea	PROPN
dpc-2847	11	5	cortese	cortese	PROPN
dpc-2847	11	6	,	,	PUNCT
dpc-2847	11	7	md	md	PROPN
dpc-2847	11	8	,	,	PUNCT
dpc-2847	11	9	dermatology	dermatology	NOUN
dpc-2847	11	10	,	,	PUNCT
dpc-2847	11	11	humanitas	humanita	NOUN
dpc-2847	11	12	research	research	NOUN
dpc-2847	11	13	hospital	hospital	NOUN
dpc-2847	11	14	–	–	PUNCT
dpc-2847	11	15	irccs	irccs	NOUN
dpc-2847	11	16	,	,	PUNCT
dpc-2847	11	17	via	via	ADP
dpc-2847	11	18	a.	a.	NOUN
dpc-2847	11	19	manzoni	manzoni	PROPN
dpc-2847	11	20	56	56	NUM
dpc-2847	11	21	,	,	PUNCT
dpc-2847	11	22	20089	20089	NUM
dpc-2847	11	23	rozzano	rozzano	PROPN
dpc-2847	11	24	(	(	PUNCT
dpc-2847	11	25	mi	mi	PROPN
dpc-2847	11	26	)	)	PUNCT
dpc-2847	11	27	,	,	PUNCT
dpc-2847	11	28	italy	italy	PROPN
dpc-2847	11	29	.	.	PUNCT
dpc-2847	12	1	e	e	X
dpc-2847	12	2	-	-	NOUN
dpc-2847	12	3	mail	mail	NOUN
dpc-2847	12	4	:	:	PUNCT
dpc-2847	13	1	andreacortese08@gmail.com	andreacortese08@gmail.com	X
dpc-2847	13	2	introduction	introduction	NOUN
dpc-2847	13	3	acute	acute	NOUN
dpc-2847	13	4	generalized	generalize	VERB
dpc-2847	13	5	exanthematous	exanthematous	ADJ
dpc-2847	13	6	pustulosis	pustulosis	NOUN
dpc-2847	13	7	(	(	PUNCT
dpc-2847	13	8	agep	agep	NOUN
dpc-2847	13	9	)	)	PUNCT
dpc-2847	13	10	is	be	AUX
dpc-2847	13	11	a	a	DET
dpc-2847	13	12	severe	severe	ADJ
dpc-2847	13	13	cutaneous	cutaneous	ADJ
dpc-2847	13	14	adverse	adverse	ADJ
dpc-2847	13	15	reaction	reaction	NOUN
dpc-2847	13	16	(	(	PUNCT
dpc-2847	13	17	scar	scar	NOUN
dpc-2847	13	18	)	)	PUNCT
dpc-2847	13	19	,	,	PUNCT
dpc-2847	13	20	with	with	ADP
dpc-2847	13	21	an	an	DET
dpc-2847	13	22	incidence	incidence	NOUN
dpc-2847	13	23	rate	rate	NOUN
dpc-2847	13	24	between	between	ADP
dpc-2847	13	25	1	1	NUM
dpc-2847	13	26	and	and	CCONJ
dpc-2847	13	27	5	5	NUM
dpc-2847	13	28	cases	case	NOUN
dpc-2847	13	29	per	per	ADP
dpc-2847	13	30	million	million	NUM
dpc-2847	13	31	per	per	ADP
dpc-2847	13	32	year	year	NOUN
dpc-2847	13	33	.	.	PUNCT
dpc-2847	14	1	clinically	clinically	ADV
dpc-2847	14	2	,	,	PUNCT
dpc-2847	14	3	agep	agep	NOUN
dpc-2847	14	4	is	be	AUX
dpc-2847	14	5	characterized	characterize	VERB
dpc-2847	14	6	by	by	ADP
dpc-2847	14	7	the	the	DET
dpc-2847	14	8	abrupt	abrupt	ADJ
dpc-2847	14	9	onset	onset	NOUN
dpc-2847	14	10	of	of	ADP
dpc-2847	14	11	edematous	edematous	ADJ
dpc-2847	14	12	erythema	erythema	NOUN
dpc-2847	14	13	and	and	CCONJ
dpc-2847	14	14	widespread	widespread	ADJ
dpc-2847	14	15	small	small	ADJ
dpc-2847	14	16	sterile	sterile	ADJ
dpc-2847	14	17	pustules	pustule	NOUN
dpc-2847	14	18	.	.	PUNCT
dpc-2847	15	1	fever	fever	NOUN
dpc-2847	15	2	with	with	ADP
dpc-2847	15	3	leukocytosis	leukocytosis	NOUN
dpc-2847	15	4	generally	generally	ADV
dpc-2847	15	5	accompany	accompany	VERB
dpc-2847	15	6	cutaneous	cutaneous	ADJ
dpc-2847	15	7	findings	finding	NOUN
dpc-2847	15	8	and	and	CCONJ
dpc-2847	15	9	mucous	mucous	ADJ
dpc-2847	15	10	membrane	membrane	NOUN
dpc-2847	15	11	may	may	AUX
dpc-2847	15	12	also	also	ADV
dpc-2847	15	13	be	be	AUX
dpc-2847	15	14	affected	affect	VERB
dpc-2847	15	15	;	;	PUNCT
dpc-2847	15	16	the	the	DET
dpc-2847	15	17	mortality	mortality	NOUN
dpc-2847	15	18	rate	rate	NOUN
dpc-2847	15	19	of	of	ADP
dpc-2847	15	20	agep	agep	NOUN
dpc-2847	15	21	is	be	AUX
dpc-2847	15	22	up	up	ADV
dpc-2847	15	23	to	to	PART
dpc-2847	15	24	5	5	NUM
dpc-2847	15	25	%	%	NOUN
dpc-2847	15	26	.	.	PUNCT
dpc-2847	16	1	the	the	DET
dpc-2847	16	2	main	main	ADJ
dpc-2847	16	3	differential	differential	ADJ
dpc-2847	16	4	diagnosis	diagnosis	NOUN
dpc-2847	16	5	of	of	ADP
dpc-2847	16	6	agep	agep	NOUN
dpc-2847	16	7	with	with	ADP
dpc-2847	16	8	generalized	generalized	ADJ
dpc-2847	16	9	pustular	pustular	ADJ
dpc-2847	16	10	psoriasis	psoriasis	NOUN
dpc-2847	16	11	is	be	AUX
dpc-2847	16	12	often	often	ADV
dpc-2847	16	13	challenging	challenge	VERB
dpc-2847	16	14	[	[	X
dpc-2847	16	15	1	1	NUM
dpc-2847	16	16	]	]	PUNCT
dpc-2847	16	17	.	.	PUNCT
dpc-2847	17	1	case	case	NOUN
dpc-2847	17	2	presentation	presentation	NOUN
dpc-2847	17	3	a	a	DET
dpc-2847	17	4	62	62	NUM
dpc-2847	17	5	-	-	PUNCT
dpc-2847	17	6	year	year	NOUN
dpc-2847	17	7	-	-	PUNCT
dpc-2847	17	8	old	old	ADJ
dpc-2847	17	9	man	man	NOUN
dpc-2847	17	10	with	with	ADP
dpc-2847	17	11	hbv	hbv	NOUN
dpc-2847	17	12	-	-	PUNCT
dpc-2847	17	13	related	relate	VERB
dpc-2847	17	14	chronic	chronic	ADJ
dpc-2847	17	15	hepatitis	hepatitis	NOUN
dpc-2847	17	16	was	be	AUX
dpc-2847	17	17	referred	refer	VERB
dpc-2847	17	18	to	to	ADP
dpc-2847	17	19	our	our	PRON
dpc-2847	17	20	dermatology	dermatology	NOUN
dpc-2847	17	21	unit	unit	NOUN
dpc-2847	17	22	for	for	ADP
dpc-2847	17	23	the	the	DET
dpc-2847	17	24	acute	acute	ADJ
dpc-2847	17	25	onset	onset	NOUN
dpc-2847	17	26	of	of	ADP
dpc-2847	17	27	skin	skin	NOUN
dpc-2847	17	28	and	and	CCONJ
dpc-2847	17	29	mucosal	mucosal	NOUN
dpc-2847	17	30	lesions	lesion	NOUN
dpc-2847	17	31	associated	associate	VERB
dpc-2847	17	32	with	with	ADP
dpc-2847	17	33	fever	fever	NOUN
dpc-2847	17	34	,	,	PUNCT
dpc-2847	17	35	7	7	NUM
dpc-2847	17	36	days	day	NOUN
dpc-2847	17	37	since	since	SCONJ
dpc-2847	17	38	the	the	DET
dpc-2847	17	39	start	start	NOUN
dpc-2847	17	40	of	of	ADP
dpc-2847	17	41	oral	oral	ADJ
dpc-2847	17	42	sorafenib	sorafenib	NOUN
dpc-2847	17	43	400	400	NUM
dpc-2847	17	44	mg	mg	NOUN
dpc-2847	17	45	twice	twice	ADV
dpc-2847	17	46	daily	daily	ADV
dpc-2847	17	47	.	.	PUNCT
dpc-2847	18	1	for	for	ADP
dpc-2847	18	2	radiation	radiation	NOUN
dpc-2847	18	3	therapy	therapy	NOUN
dpc-2847	18	4	-	-	PUNCT
dpc-2847	18	5	refractory	refractory	NOUN
dpc-2847	18	6	stage	stage	NOUN
dpc-2847	18	7	iv	iv	VERB
dpc-2847	18	8	hepatocellular	hepatocellular	ADJ
dpc-2847	18	9	carcinoma	carcinoma	NOUN
dpc-2847	18	10	.	.	PUNCT
dpc-2847	19	1	past	past	ADP
dpc-2847	19	2	medical	medical	ADJ
dpc-2847	19	3	history	history	NOUN
dpc-2847	19	4	was	be	AUX
dpc-2847	19	5	negative	negative	ADJ
dpc-2847	19	6	for	for	ADP
dpc-2847	19	7	psoriasis	psoriasis	NOUN
dpc-2847	19	8	.	.	PUNCT
dpc-2847	20	1	on	on	ADP
dpc-2847	20	2	physical	physical	ADJ
dpc-2847	20	3	examination	examination	NOUN
dpc-2847	20	4	,	,	PUNCT
dpc-2847	20	5	numerous	numerous	ADJ
dpc-2847	20	6	disseminated	disseminate	VERB
dpc-2847	20	7	tiny	tiny	ADJ
dpc-2847	20	8	non	non	ADJ
dpc-2847	20	9	-	-	ADJ
dpc-2847	20	10	follicular	follicular	ADJ
dpc-2847	20	11	pustules	pustule	NOUN
dpc-2847	20	12	were	be	AUX
dpc-2847	20	13	observed	observe	VERB
dpc-2847	20	14	overlying	overlie	VERB
dpc-2847	20	15	confluent	confluent	ADJ
dpc-2847	20	16	erythematous	erythematous	ADJ
dpc-2847	20	17	macules	macule	NOUN
dpc-2847	20	18	on	on	ADP
dpc-2847	20	19	his	his	PRON
dpc-2847	20	20	trunk	trunk	NOUN
dpc-2847	20	21	and	and	CCONJ
dpc-2847	20	22	limbs	limb	NOUN
dpc-2847	20	23	,	,	PUNCT
dpc-2847	20	24	involving	involve	VERB
dpc-2847	20	25	about	about	ADV
dpc-2847	20	26	75	75	NUM
dpc-2847	20	27	%	%	NOUN
dpc-2847	20	28	of	of	ADP
dpc-2847	20	29	the	the	DET
dpc-2847	20	30	body	body	NOUN
dpc-2847	20	31	surface	surface	NOUN
dpc-2847	20	32	area	area	NOUN
dpc-2847	20	33	(	(	PUNCT
dpc-2847	20	34	figure	figure	NOUN
dpc-2847	20	35	1	1	NUM
dpc-2847	20	36	)	)	PUNCT
dpc-2847	20	37	.	.	PUNCT
dpc-2847	21	1	furred	furred	ADJ
dpc-2847	21	2	tongue	tongue	NOUN
dpc-2847	21	3	and	and	CCONJ
dpc-2847	21	4	desquamation	desquamation	NOUN
dpc-2847	21	5	of	of	ADP
dpc-2847	21	6	the	the	DET
dpc-2847	21	7	lips	lip	NOUN
dpc-2847	21	8	were	be	AUX
dpc-2847	21	9	also	also	ADV
dpc-2847	21	10	present	present	ADJ
dpc-2847	21	11	.	.	PUNCT
dpc-2847	22	1	body	body	NOUN
dpc-2847	22	2	temperature	temperature	NOUN
dpc-2847	22	3	was	be	AUX
dpc-2847	22	4	38.5	38.5	NUM
dpc-2847	22	5	°	°	NOUN
dpc-2847	22	6	c	c	NOUN
dpc-2847	22	7	.	.	PUNCT
dpc-2847	23	1	no	no	DET
dpc-2847	23	2	enlarged	enlarged	ADJ
dpc-2847	23	3	lymph	lymph	NOUN
dpc-2847	23	4	nodes	node	NOUN
dpc-2847	23	5	or	or	CCONJ
dpc-2847	23	6	hepatosplenomegaly	hepatosplenomegaly	NOUN
dpc-2847	23	7	were	be	AUX
dpc-2847	23	8	noticed	notice	VERB
dpc-2847	23	9	.	.	PUNCT
dpc-2847	24	1	complete	complete	ADJ
dpc-2847	24	2	blood	blood	NOUN
dpc-2847	24	3	count	count	NOUN
dpc-2847	24	4	showed	show	VERB
dpc-2847	24	5	leukocytosis	leukocytosis	NOUN
dpc-2847	24	6	with	with	ADP
dpc-2847	24	7	relative	relative	ADJ
dpc-2847	24	8	neutrophilia	neutrophilia	PROPN
dpc-2847	24	9	(	(	PUNCT
dpc-2847	24	10	80	80	NUM
dpc-2847	24	11	%	%	NOUN
dpc-2847	24	12	,	,	PUNCT
dpc-2847	24	13	normal	normal	ADJ
dpc-2847	24	14	range	range	NOUN
dpc-2847	24	15	50%-75	50%-75	NUM
dpc-2847	24	16	%	%	NOUN
dpc-2847	24	17	)	)	PUNCT
dpc-2847	24	18	;	;	PUNCT
dpc-2847	24	19	serum	serum	NOUN
dpc-2847	24	20	bilirubin	bilirubin	NOUN
dpc-2847	24	21	level	level	NOUN
dpc-2847	24	22	was	be	AUX
dpc-2847	24	23	increased	increase	VERB
dpc-2847	24	24	(	(	PUNCT
dpc-2847	24	25	3.0	3.0	NUM
dpc-2847	24	26	mg	mg	PROPN
dpc-2847	24	27	/	/	SYM
dpc-2847	24	28	dl	dl	PROPN
dpc-2847	24	29	,	,	PUNCT
dpc-2847	24	30	normal	normal	ADJ
dpc-2847	24	31	range	range	VERB
dpc-2847	24	32	0.3	0.3	NUM
dpc-2847	24	33	-	-	SYM
dpc-2847	24	34	1.2	1.2	NUM
dpc-2847	24	35	mg	mg	PROPN
dpc-2847	24	36	/	/	SYM
dpc-2847	24	37	dl	dl	NOUN
dpc-2847	24	38	)	)	PUNCT
dpc-2847	24	39	.	.	PUNCT
dpc-2847	25	1	blood	blood	NOUN
dpc-2847	25	2	and	and	CCONJ
dpc-2847	25	3	skin	skin	NOUN
dpc-2847	25	4	cultures	culture	NOUN
dpc-2847	25	5	resulted	result	VERB
dpc-2847	25	6	negative	negative	ADJ
dpc-2847	25	7	.	.	PUNCT
dpc-2847	26	1	histological	histological	ADJ
dpc-2847	26	2	examination	examination	NOUN
dpc-2847	26	3	of	of	ADP
dpc-2847	26	4	a	a	DET
dpc-2847	26	5	skin	skin	NOUN
dpc-2847	26	6	biopsy	biopsy	NOUN
dpc-2847	26	7	showed	show	VERB
dpc-2847	26	8	multifocal	multifocal	ADJ
dpc-2847	26	9	spongiosis	spongiosis	NOUN
dpc-2847	26	10	in	in	ADP
dpc-2847	26	11	the	the	DET
dpc-2847	26	12	epidermis	epidermis	NOUN
dpc-2847	26	13	,	,	PUNCT
dpc-2847	26	14	with	with	ADP
dpc-2847	26	15	intraepidermal	intraepidermal	ADJ
dpc-2847	26	16	pustules	pustule	NOUN
dpc-2847	26	17	containing	contain	VERB
dpc-2847	26	18	fibrin	fibrin	NOUN
dpc-2847	26	19	and	and	CCONJ
dpc-2847	26	20	neutrophils	neutrophil	NOUN
dpc-2847	26	21	.	.	PUNCT
dpc-2847	27	1	in	in	ADP
dpc-2847	27	2	the	the	DET
dpc-2847	27	3	superficial	superficial	ADJ
dpc-2847	27	4	dermis	dermis	NOUN
dpc-2847	27	5	,	,	PUNCT
dpc-2847	27	6	a	a	DET
dpc-2847	27	7	mixed	mixed	ADJ
dpc-2847	27	8	inflammatory	inflammatory	ADJ
dpc-2847	27	9	infiltrate	infiltrate	NOUN
dpc-2847	27	10	composed	compose	VERB
dpc-2847	27	11	of	of	ADP
dpc-2847	27	12	scattered	scatter	VERB
dpc-2847	27	13	neutrophils	neutrophil	NOUN
dpc-2847	27	14	and	and	CCONJ
dpc-2847	27	15	lymphocytes	lymphocyte	NOUN
dpc-2847	27	16	was	be	AUX
dpc-2847	27	17	present	present	ADJ
dpc-2847	27	18	(	(	PUNCT
dpc-2847	27	19	figure	figure	NOUN
dpc-2847	27	20	2	2	NUM
dpc-2847	27	21	)	)	PUNCT
dpc-2847	27	22	.	.	PUNCT
dpc-2847	28	1	according	accord	VERB
dpc-2847	28	2	to	to	ADP
dpc-2847	28	3	the	the	DET
dpc-2847	28	4	validation	validation	NOUN
dpc-2847	28	5	score	score	NOUN
dpc-2847	28	6	of	of	ADP
dpc-2847	28	7	the	the	DET
dpc-2847	28	8	euroscar	euroscar	NOUN
dpc-2847	28	9	study	study	NOUN
dpc-2847	28	10	group	group	NOUN
dpc-2847	28	11	[	[	X
dpc-2847	28	12	2	2	NUM
dpc-2847	28	13	]	]	PUNCT
dpc-2847	28	14	,	,	PUNCT
dpc-2847	28	15	a	a	DET
dpc-2847	28	16	diagnosis	diagnosis	NOUN
dpc-2847	28	17	of	of	ADP
dpc-2847	28	18	acute	acute	ADJ
dpc-2847	28	19	generalized	generalize	VERB
dpc-2847	28	20	exanthematous	exanthematous	ADJ
dpc-2847	28	21	pustulosis	pustulosis	NOUN
dpc-2847	28	22	(	(	PUNCT
dpc-2847	28	23	agep	agep	NOUN
dpc-2847	28	24	)	)	PUNCT
dpc-2847	28	25	was	be	AUX
dpc-2847	28	26	made	make	VERB
dpc-2847	28	27	;	;	PUNCT
dpc-2847	28	28	using	use	VERB
dpc-2847	28	29	the	the	DET
dpc-2847	28	30	naranjo	naranjo	PROPN
dpc-2847	28	31	scale	scale	NOUN
dpc-2847	28	32	[	[	X
dpc-2847	28	33	3	3	X
dpc-2847	28	34	]	]	X
dpc-2847	28	35	the	the	DET
dpc-2847	28	36	2	2	NUM
dpc-2847	28	37	research	research	NOUN
dpc-2847	28	38	letter	letter	NOUN
dpc-2847	29	1	|	|	ADV
dpc-2847	29	2	dermatol	dermatol	ADJ
dpc-2847	29	3	pract	pract	NOUN
dpc-2847	29	4	concept	concept	NOUN
dpc-2847	29	5	.	.	PUNCT
dpc-2847	30	1	2023;13(2):e2023130	2023;13(2):e2023130	NUM
dpc-2847	30	2	skin	skin	NOUN
dpc-2847	30	3	reaction	reaction	NOUN
dpc-2847	30	4	collected	collect	VERB
dpc-2847	30	5	six	six	NUM
dpc-2847	30	6	points	point	NOUN
dpc-2847	30	7	and	and	CCONJ
dpc-2847	30	8	was	be	AUX
dpc-2847	30	9	considered	consider	VERB
dpc-2847	30	10	probably	probably	ADV
dpc-2847	30	11	relate	relate	VERB
dpc-2847	30	12	”	"	PUNCT
dpc-2847	30	13	to	to	ADP
dpc-2847	30	14	sorafenib	sorafenib	PROPN
dpc-2847	30	15	(	(	PUNCT
dpc-2847	30	16	figure	figure	NOUN
dpc-2847	30	17	3	3	NUM
dpc-2847	30	18	)	)	PUNCT
dpc-2847	30	19	,	,	PUNCT
dpc-2847	30	20	so	so	CCONJ
dpc-2847	30	21	the	the	DET
dpc-2847	30	22	drug	drug	NOUN
dpc-2847	30	23	was	be	AUX
dpc-2847	30	24	discontinued	discontinue	VERB
dpc-2847	30	25	with	with	ADP
dpc-2847	30	26	steady	steady	ADJ
dpc-2847	30	27	improvement	improvement	NOUN
dpc-2847	30	28	in	in	ADP
dpc-2847	30	29	the	the	DET
dpc-2847	30	30	following	follow	VERB
dpc-2847	30	31	days	day	NOUN
dpc-2847	30	32	.	.	PUNCT
dpc-2847	31	1	conclusions	conclusion	NOUN
dpc-2847	31	2	sorafenib	sorafenib	PROPN
dpc-2847	31	3	is	be	AUX
dpc-2847	31	4	an	an	DET
dpc-2847	31	5	oral	oral	ADJ
dpc-2847	31	6	multi	multi	ADJ
dpc-2847	31	7	-	-	ADJ
dpc-2847	31	8	kinase	kinase	ADJ
dpc-2847	31	9	inhibitor	inhibitor	NOUN
dpc-2847	31	10	that	that	PRON
dpc-2847	31	11	mainly	mainly	ADV
dpc-2847	31	12	targets	target	VERB
dpc-2847	31	13	c	c	NOUN
dpc-2847	31	14	-	-	PUNCT
dpc-2847	31	15	raf	raf	NOUN
dpc-2847	31	16	,	,	PUNCT
dpc-2847	31	17	b	b	X
dpc-2847	31	18	-	-	PUNCT
dpc-2847	31	19	raf	raf	NOUN
dpc-2847	31	20	,	,	PUNCT
dpc-2847	31	21	vascular	vascular	ADJ
dpc-2847	31	22	endothelial	endothelial	ADJ
dpc-2847	31	23	growth	growth	NOUN
dpc-2847	31	24	factor	factor	NOUN
dpc-2847	31	25	(	(	PUNCT
dpc-2847	31	26	vegf	vegf	NOUN
dpc-2847	31	27	)	)	PUNCT
dpc-2847	31	28	receptors	receptor	NOUN
dpc-2847	31	29	,	,	PUNCT
dpc-2847	31	30	and	and	CCONJ
dpc-2847	31	31	platelet	platelet	ADJ
dpc-2847	31	32	-	-	PUNCT
dpc-2847	31	33	derived	derive	VERB
dpc-2847	31	34	growth	growth	NOUN
dpc-2847	31	35	factor	factor	NOUN
dpc-2847	31	36	receptor	receptor	NOUN
dpc-2847	31	37	(	(	PUNCT
dpc-2847	31	38	pdgfr	pdgfr	ADJ
dpc-2847	31	39	)	)	PUNCT
dpc-2847	31	40	.	.	PUNCT
dpc-2847	32	1	the	the	DET
dpc-2847	32	2	drug	drug	NOUN
dpc-2847	32	3	is	be	AUX
dpc-2847	32	4	approved	approve	VERB
dpc-2847	32	5	for	for	ADP
dpc-2847	32	6	the	the	DET
dpc-2847	32	7	treatment	treatment	NOUN
dpc-2847	32	8	of	of	ADP
dpc-2847	32	9	both	both	CCONJ
dpc-2847	32	10	unresectable	unresectable	ADJ
dpc-2847	32	11	hepatocellular	hepatocellular	ADJ
dpc-2847	32	12	carcinoma	carcinoma	NOUN
dpc-2847	32	13	and	and	CCONJ
dpc-2847	32	14	advanced	advanced	ADJ
dpc-2847	32	15	renal	renal	ADJ
dpc-2847	32	16	cell	cell	NOUN
dpc-2847	32	17	carcinoma	carcinoma	NOUN
dpc-2847	32	18	.	.	PUNCT
dpc-2847	33	1	up	up	ADP
dpc-2847	33	2	to	to	PART
dpc-2847	33	3	60	60	NUM
dpc-2847	33	4	%	%	NOUN
dpc-2847	33	5	patients	patient	NOUN
dpc-2847	33	6	treated	treat	VERB
dpc-2847	33	7	with	with	ADP
dpc-2847	33	8	sorafenib	sorafenib	NOUN
dpc-2847	33	9	experience	experience	VERB
dpc-2847	33	10	cutaneous	cutaneous	ADJ
dpc-2847	33	11	adverse	adverse	ADJ
dpc-2847	33	12	events	event	NOUN
dpc-2847	33	13	,	,	PUNCT
dpc-2847	33	14	including	include	VERB
dpc-2847	33	15	hand	hand	NOUN
dpc-2847	33	16	-	-	PUNCT
dpc-2847	33	17	foot	foot	NOUN
dpc-2847	33	18	skin	skin	NOUN
dpc-2847	33	19	reactions	reaction	NOUN
dpc-2847	33	20	,	,	PUNCT
dpc-2847	33	21	maculo	maculo	NOUN
dpc-2847	33	22	-	-	PUNCT
dpc-2847	33	23	papular	papular	ADJ
dpc-2847	33	24	exanthem	exanthem	NOUN
dpc-2847	33	25	,	,	PUNCT
dpc-2847	33	26	pruritus	pruritus	NOUN
dpc-2847	33	27	,	,	PUNCT
dpc-2847	33	28	alopecia	alopecia	NOUN
dpc-2847	33	29	,	,	PUNCT
dpc-2847	33	30	subungual	subungual	ADJ
dpc-2847	33	31	splinter	splinter	NOUN
dpc-2847	33	32	hemorrhages	hemorrhage	NOUN
dpc-2847	33	33	,	,	PUNCT
dpc-2847	33	34	seborrheic	seborrheic	ADJ
dpc-2847	33	35	dermatitis	dermatitis	NOUN
dpc-2847	33	36	-	-	PUNCT
dpc-2847	33	37	like	like	ADJ
dpc-2847	33	38	eruption	eruption	NOUN
dpc-2847	33	39	and	and	CCONJ
dpc-2847	33	40	erythema	erythema	ADJ
dpc-2847	33	41	multiforme	multiforme	NOUN
dpc-2847	34	1	[	[	X
dpc-2847	34	2	4	4	NUM
dpc-2847	34	3	]	]	PUNCT
dpc-2847	34	4	.	.	PUNCT
dpc-2847	35	1	agep	agep	PROPN
dpc-2847	35	2	has	have	AUX
dpc-2847	35	3	been	be	AUX
dpc-2847	35	4	most	most	ADV
dpc-2847	35	5	commonly	commonly	ADV
dpc-2847	35	6	associated	associate	VERB
dpc-2847	35	7	with	with	ADP
dpc-2847	35	8	aminopenicillins	aminopenicillin	NOUN
dpc-2847	35	9	,	,	PUNCT
dpc-2847	35	10	quinolones	quinolone	NOUN
dpc-2847	35	11	,	,	PUNCT
dpc-2847	35	12	chloroquine	chloroquine	NOUN
dpc-2847	35	13	and	and	CCONJ
dpc-2847	35	14	sulphonamides	sulphonamide	NOUN
dpc-2847	35	15	,	,	PUNCT
dpc-2847	35	16	and	and	CCONJ
dpc-2847	35	17	to	to	ADP
dpc-2847	35	18	our	our	PRON
dpc-2847	35	19	knowledge	knowledge	NOUN
dpc-2847	35	20	only	only	ADV
dpc-2847	35	21	three	three	NUM
dpc-2847	35	22	cases	case	NOUN
dpc-2847	35	23	of	of	ADP
dpc-2847	35	24	sorafenib	sorafenib	NOUN
dpc-2847	35	25	-	-	PUNCT
dpc-2847	35	26	induced	induce	VERB
dpc-2847	35	27	pustular	pustular	ADJ
dpc-2847	35	28	reactions	reaction	NOUN
dpc-2847	35	29	were	be	AUX
dpc-2847	35	30	figure	figure	NOUN
dpc-2847	35	31	1	1	NUM
dpc-2847	35	32	.	.	PUNCT
dpc-2847	35	33	confluent	confluent	ADJ
dpc-2847	35	34	erythematous	erythematous	ADJ
dpc-2847	35	35	macules	macule	NOUN
dpc-2847	35	36	on	on	ADP
dpc-2847	35	37	his	his	PRON
dpc-2847	35	38	trunk	trunk	NOUN
dpc-2847	35	39	and	and	CCONJ
dpc-2847	35	40	limbs	limb	NOUN
dpc-2847	35	41	,	,	PUNCT
dpc-2847	35	42	involving	involve	VERB
dpc-2847	35	43	about	about	ADV
dpc-2847	35	44	75	75	NUM
dpc-2847	35	45	%	%	NOUN
dpc-2847	35	46	of	of	ADP
dpc-2847	35	47	the	the	DET
dpc-2847	35	48	body	body	NOUN
dpc-2847	35	49	surface	surface	NOUN
dpc-2847	35	50	area	area	NOUN
dpc-2847	35	51	,	,	PUNCT
dpc-2847	35	52	d	d	NOUN
dpc-2847	35	53	with	with	ADP
dpc-2847	35	54	overlying	overlie	VERB
dpc-2847	35	55	disseminated	disseminate	VERB
dpc-2847	35	56	tiny	tiny	ADJ
dpc-2847	35	57	non	non	ADJ
dpc-2847	35	58	-	-	ADJ
dpc-2847	35	59	follicular	follicular	ADJ
dpc-2847	35	60	pustules	pustule	NOUN
dpc-2847	35	61	.	.	PUNCT
dpc-2847	36	1	figure	figure	NOUN
dpc-2847	36	2	2	2	NUM
dpc-2847	36	3	.	.	PUNCT
dpc-2847	36	4	intraepidermal	intraepidermal	ADJ
dpc-2847	36	5	pustule	pustule	NOUN
dpc-2847	36	6	containing	contain	VERB
dpc-2847	36	7	fibrin	fibrin	NOUN
dpc-2847	36	8	and	and	CCONJ
dpc-2847	36	9	neutrophils	neutrophil	NOUN
dpc-2847	36	10	;	;	PUNCT
dpc-2847	36	11	in	in	ADP
dpc-2847	36	12	the	the	DET
dpc-2847	36	13	superficial	superficial	ADJ
dpc-2847	36	14	dermis	dermis	NOUN
dpc-2847	36	15	,	,	PUNCT
dpc-2847	36	16	a	a	DET
dpc-2847	36	17	mixed	mixed	ADJ
dpc-2847	36	18	inflammatory	inflammatory	ADJ
dpc-2847	36	19	infiltrate	infiltrate	ADJ
dpc-2847	36	20	composed	compose	VERB
dpc-2847	36	21	scattered	scatter	VERB
dpc-2847	36	22	neutrophils	neutrophil	NOUN
dpc-2847	36	23	and	and	CCONJ
dpc-2847	36	24	lymphocytes	lymphocyte	NOUN
dpc-2847	36	25	was	be	AUX
dpc-2847	36	26	present	present	ADJ
dpc-2847	36	27	.	.	PUNCT
dpc-2847	37	1	research	research	NOUN
dpc-2847	37	2	letter	letter	NOUN
dpc-2847	37	3	|	|	ADV
dpc-2847	37	4	dermatol	dermatol	ADJ
dpc-2847	37	5	pract	pract	NOUN
dpc-2847	37	6	concept	concept	NOUN
dpc-2847	37	7	.	.	PUNCT
dpc-2847	38	1	2023;13(2):e2023130	2023;13(2):e2023130	NUM
dpc-2847	38	2	3	3	NUM
dpc-2847	38	3	published	publish	VERB
dpc-2847	38	4	:	:	PUNCT
dpc-2847	38	5	one	one	NUM
dpc-2847	38	6	of	of	ADP
dpc-2847	38	7	them	they	PRON
dpc-2847	38	8	defined	define	VERB
dpc-2847	38	9	as	as	ADP
dpc-2847	38	10	acute	acute	ADJ
dpc-2847	38	11	localized	localize	VERB
dpc-2847	38	12	exanthematous	exanthematous	ADJ
dpc-2847	38	13	pustulosis	pustulosis	NOUN
dpc-2847	38	14	(	(	PUNCT
dpc-2847	38	15	alep	alep	NOUN
dpc-2847	38	16	)	)	PUNCT
dpc-2847	39	1	[	[	X
dpc-2847	39	2	5	5	NUM
dpc-2847	39	3	]	]	PUNCT
dpc-2847	39	4	,	,	PUNCT
dpc-2847	39	5	while	while	SCONJ
dpc-2847	39	6	two	two	NUM
dpc-2847	39	7	reported	report	VERB
dpc-2847	39	8	as	as	ADP
dpc-2847	39	9	agep	agep	NOUN
dpc-2847	39	10	[	[	X
dpc-2847	39	11	6,7	6,7	NUM
dpc-2847	39	12	]	]	PUNCT
dpc-2847	39	13	.	.	PUNCT
dpc-2847	40	1	these	these	DET
dpc-2847	40	2	evidence	evidence	NOUN
dpc-2847	40	3	may	may	AUX
dpc-2847	40	4	suggest	suggest	VERB
dpc-2847	40	5	an	an	DET
dpc-2847	40	6	increasing	increase	VERB
dpc-2847	40	7	incidence	incidence	NOUN
dpc-2847	40	8	of	of	ADP
dpc-2847	40	9	sorafenib	sorafenib	NOUN
dpc-2847	40	10	-	-	PUNCT
dpc-2847	40	11	induced	induce	VERB
dpc-2847	40	12	agep	agep	NOUN
dpc-2847	40	13	due	due	ADP
dpc-2847	40	14	to	to	ADP
dpc-2847	40	15	the	the	DET
dpc-2847	40	16	relatively	relatively	ADV
dpc-2847	40	17	recent	recent	ADJ
dpc-2847	40	18	introduction	introduction	NOUN
dpc-2847	40	19	use	use	NOUN
dpc-2847	40	20	of	of	ADP
dpc-2847	40	21	this	this	DET
dpc-2847	40	22	kinase	kinase	NOUN
dpc-2847	40	23	-	-	PUNCT
dpc-2847	40	24	inhibitor	inhibitor	NOUN
dpc-2847	40	25	.	.	PUNCT
dpc-2847	41	1	we	we	PRON
dpc-2847	41	2	therefore	therefore	ADV
dpc-2847	41	3	underline	underline	VERB
dpc-2847	41	4	the	the	DET
dpc-2847	41	5	importance	importance	NOUN
dpc-2847	41	6	of	of	ADP
dpc-2847	41	7	early	early	ADJ
dpc-2847	41	8	diagnosis	diagnosis	NOUN
dpc-2847	41	9	of	of	ADP
dpc-2847	41	10	agep	agep	NOUN
dpc-2847	41	11	during	during	ADP
dpc-2847	41	12	sorafenib	sorafenib	NOUN
dpc-2847	41	13	therapy	therapy	NOUN
dpc-2847	41	14	,	,	PUNCT
dpc-2847	41	15	in	in	ADP
dpc-2847	41	16	order	order	NOUN
dpc-2847	41	17	to	to	PART
dpc-2847	41	18	promptly	promptly	ADV
dpc-2847	41	19	withdraw	withdraw	VERB
dpc-2847	41	20	the	the	DET
dpc-2847	41	21	causative	causative	ADJ
dpc-2847	41	22	drug	drug	NOUN
dpc-2847	41	23	and	and	CCONJ
dpc-2847	41	24	at	at	ADP
dpc-2847	41	25	the	the	DET
dpc-2847	41	26	same	same	ADJ
dpc-2847	41	27	time	time	NOUN
dpc-2847	41	28	to	to	PART
dpc-2847	41	29	consider	consider	VERB
dpc-2847	41	30	other	other	ADJ
dpc-2847	41	31	therapeutic	therapeutic	ADJ
dpc-2847	41	32	options	option	NOUN
dpc-2847	41	33	for	for	ADP
dpc-2847	41	34	metastatic	metastatic	ADJ
dpc-2847	41	35	cancer	cancer	NOUN
dpc-2847	41	36	.	.	PUNCT
dpc-2847	42	1	references	reference	NOUN
dpc-2847	42	2	1	1	NUM
dpc-2847	42	3	.	.	PUNCT
dpc-2847	42	4	sidoroff	sidoroff	PROPN
dpc-2847	42	5	a	a	PRON
dpc-2847	42	6	,	,	PUNCT
dpc-2847	42	7	halevy	halevy	NOUN
dpc-2847	42	8	s	s	PART
dpc-2847	42	9	,	,	PUNCT
dpc-2847	42	10	bavinck	bavinck	PROPN
dpc-2847	42	11	jn	jn	PROPN
dpc-2847	42	12	,	,	PUNCT
dpc-2847	42	13	vaillant	vaillant	PROPN
dpc-2847	42	14	l	l	PROPN
dpc-2847	42	15	,	,	PUNCT
dpc-2847	43	1	roujeau	roujeau	PROPN
dpc-2847	43	2	jc	jc	PROPN
dpc-2847	43	3	.	.	PROPN
dpc-2847	43	4	acute	acute	PROPN
dpc-2847	43	5	generalized	generalize	VERB
dpc-2847	43	6	exanthematous	exanthematous	ADJ
dpc-2847	43	7	pustulosis	pustulosis	NOUN
dpc-2847	43	8	(	(	PUNCT
dpc-2847	43	9	agep	agep	NOUN
dpc-2847	43	10	):	):	PUNCT
dpc-2847	43	11	a	a	DET
dpc-2847	43	12	clinical	clinical	ADJ
dpc-2847	43	13	reaction	reaction	NOUN
dpc-2847	43	14	pattern	pattern	NOUN
dpc-2847	43	15	.	.	PUNCT
dpc-2847	44	1	j	j	PROPN
dpc-2847	44	2	cutan	cutan	PROPN
dpc-2847	44	3	pathol	pathol	PROPN
dpc-2847	44	4	.	.	PUNCT
dpc-2847	45	1	2001;28(3):113	2001;28(3):113	PROPN
dpc-2847	45	2	-	-	PUNCT
dpc-2847	45	3	119	119	PROPN
dpc-2847	45	4	.	.	PUNCT
dpc-2847	46	1	doi	doi	NOUN
dpc-2847	46	2	:	:	PUNCT
dpc-2847	46	3	10.1034	10.1034	NUM
dpc-2847	46	4	/	/	SYM
dpc-2847	46	5	j.1600	j.1600	NOUN
dpc-2847	46	6	-	-	PUNCT
dpc-2847	46	7	0560.2001.028003113.x	0560.2001.028003113.x	NOUN
dpc-2847	46	8	.	.	PUNCT
dpc-2847	47	1	pmid	pmid	NOUN
dpc-2847	47	2	:	:	PUNCT
dpc-2847	47	3	11168761	11168761	NUM
dpc-2847	47	4	.	.	PUNCT
dpc-2847	48	1	2	2	X
dpc-2847	48	2	.	.	X
dpc-2847	48	3	sidoroff	sidoroff	PROPN
dpc-2847	48	4	a	a	PRON
dpc-2847	48	5	,	,	PUNCT
dpc-2847	48	6	dunant	dunant	NOUN
dpc-2847	48	7	a	a	NOUN
dpc-2847	48	8	,	,	PUNCT
dpc-2847	48	9	viboud	viboud	ADJ
dpc-2847	48	10	c	c	NOUN
dpc-2847	48	11	,	,	PUNCT
dpc-2847	48	12	et	et	PROPN
dpc-2847	48	13	al	al	PROPN
dpc-2847	48	14	.	.	PUNCT
dpc-2847	49	1	risk	risk	NOUN
dpc-2847	49	2	factors	factor	NOUN
dpc-2847	49	3	for	for	ADP
dpc-2847	49	4	acute	acute	ADJ
dpc-2847	49	5	generalized	generalize	VERB
dpc-2847	49	6	exanthematous	exanthematous	ADJ
dpc-2847	49	7	pustulosis	pustulosis	NOUN
dpc-2847	49	8	(	(	PUNCT
dpc-2847	49	9	agep)-results	agep)-result	NOUN
dpc-2847	49	10	of	of	ADP
dpc-2847	49	11	a	a	DET
dpc-2847	49	12	multinational	multinational	ADJ
dpc-2847	49	13	case	case	NOUN
dpc-2847	49	14	-	-	PUNCT
dpc-2847	49	15	control	control	NOUN
dpc-2847	49	16	study	study	NOUN
dpc-2847	49	17	(	(	PUNCT
dpc-2847	49	18	euroscar	euroscar	PROPN
dpc-2847	49	19	)	)	PUNCT
dpc-2847	49	20	.	.	PUNCT
dpc-2847	50	1	br	br	PROPN
dpc-2847	50	2	j	j	PROPN
dpc-2847	50	3	dermatol	dermatol	NOUN
dpc-2847	50	4	.	.	PUNCT
dpc-2847	51	1	2007;157(5):989996	2007;157(5):989996	X
dpc-2847	51	2	.	.	PUNCT
dpc-2847	51	3	doi	doi	NOUN
dpc-2847	51	4	:	:	PUNCT
dpc-2847	51	5	10.1111	10.1111	NUM
dpc-2847	51	6	/	/	SYM
dpc-2847	51	7	j.1365	j.1365	NOUN
dpc-2847	51	8	-	-	PUNCT
dpc-2847	51	9	2133.2007.08156.x	2133.2007.08156.x	NOUN
dpc-2847	51	10	.	.	PUNCT
dpc-2847	52	1	pmid	pmid	NOUN
dpc-2847	52	2	:	:	PUNCT
dpc-2847	52	3	17854366	17854366	NUM
dpc-2847	52	4	.	.	PUNCT
dpc-2847	53	1	3	3	X
dpc-2847	53	2	.	.	X
dpc-2847	53	3	naranjo	naranjo	PROPN
dpc-2847	53	4	ca	ca	PROPN
dpc-2847	53	5	,	,	PUNCT
dpc-2847	53	6	busto	busto	NOUN
dpc-2847	53	7	u	u	NOUN
dpc-2847	53	8	,	,	PUNCT
dpc-2847	53	9	sellers	seller	VERB
dpc-2847	53	10	em	em	PRON
dpc-2847	53	11	,	,	PUNCT
dpc-2847	53	12	et	et	PROPN
dpc-2847	53	13	al	al	PROPN
dpc-2847	53	14	.	.	PUNCT
dpc-2847	54	1	a	a	DET
dpc-2847	54	2	method	method	NOUN
dpc-2847	54	3	for	for	ADP
dpc-2847	54	4	estimating	estimate	VERB
dpc-2847	54	5	the	the	DET
dpc-2847	54	6	probability	probability	NOUN
dpc-2847	54	7	of	of	ADP
dpc-2847	54	8	adverse	adverse	ADJ
dpc-2847	54	9	drug	drug	NOUN
dpc-2847	54	10	reactions	reaction	NOUN
dpc-2847	54	11	.	.	PUNCT
dpc-2847	55	1	clin	clin	PROPN
dpc-2847	55	2	pharmacol	pharmacol	PROPN
dpc-2847	55	3	ther	ther	ADV
dpc-2847	55	4	.	.	PUNCT
dpc-2847	56	1	1981;30(2):239	1981;30(2):239	NUM
dpc-2847	56	2	-	-	SYM
dpc-2847	56	3	245	245	NUM
dpc-2847	56	4	.	.	PUNCT
dpc-2847	56	5	doi	doi	NOUN
dpc-2847	56	6	:	:	PUNCT
dpc-2847	56	7	10.1038	10.1038	NUM
dpc-2847	56	8	/	/	SYM
dpc-2847	56	9	clpt.1981.154	clpt.1981.154	PROPN
dpc-2847	56	10	.	.	PUNCT
dpc-2847	57	1	pmid	pmid	NOUN
dpc-2847	57	2	:	:	PUNCT
dpc-2847	57	3	7249508	7249508	NUM
dpc-2847	57	4	.	.	PUNCT
dpc-2847	58	1	4	4	X
dpc-2847	58	2	.	.	X
dpc-2847	58	3	bracarda	bracarda	PROPN
dpc-2847	58	4	s	s	PART
dpc-2847	58	5	,	,	PUNCT
dpc-2847	58	6	ruggeri	ruggeri	VERB
dpc-2847	58	7	em	em	PRON
dpc-2847	58	8	,	,	PUNCT
dpc-2847	58	9	monti	monti	PROPN
dpc-2847	58	10	m	m	PROPN
dpc-2847	58	11	,	,	PUNCT
dpc-2847	58	12	et	et	PROPN
dpc-2847	58	13	al	al	PROPN
dpc-2847	58	14	.	.	PROPN
dpc-2847	59	1	early	early	ADJ
dpc-2847	59	2	detection	detection	NOUN
dpc-2847	59	3	,	,	PUNCT
dpc-2847	59	4	prevention	prevention	NOUN
dpc-2847	59	5	and	and	CCONJ
dpc-2847	59	6	management	management	NOUN
dpc-2847	59	7	of	of	ADP
dpc-2847	59	8	cutaneous	cutaneous	ADJ
dpc-2847	59	9	adverse	adverse	ADJ
dpc-2847	59	10	events	event	NOUN
dpc-2847	59	11	due	due	ADP
dpc-2847	59	12	to	to	ADP
dpc-2847	59	13	sorafenib	sorafenib	NOUN
dpc-2847	59	14	:	:	PUNCT
dpc-2847	59	15	recommendations	recommendation	NOUN
dpc-2847	59	16	from	from	ADP
dpc-2847	59	17	the	the	DET
dpc-2847	59	18	sorafenib	sorafenib	NOUN
dpc-2847	59	19	working	working	NOUN
dpc-2847	59	20	group	group	NOUN
dpc-2847	59	21	.	.	PUNCT
dpc-2847	60	1	crit	crit	PROPN
dpc-2847	60	2	rev	rev	VERB
dpc-2847	60	3	oncol	oncol	ADJ
dpc-2847	60	4	hematol	hematol	NOUN
dpc-2847	60	5	.	.	PUNCT
dpc-2847	61	1	2012;82(3):378	2012;82(3):378	NOUN
dpc-2847	61	2	-	-	PUNCT
dpc-2847	61	3	386	386	NUM
dpc-2847	61	4	.	.	PUNCT
dpc-2847	61	5	doi	doi	NOUN
dpc-2847	61	6	:	:	PUNCT
dpc-2847	61	7	10.1016	10.1016	NUM
dpc-2847	61	8	/	/	SYM
dpc-2847	61	9	j.	j.	PROPN
dpc-2847	61	10	critrevonc.2011.08.005	critrevonc.2011.08.005	PROPN
dpc-2847	61	11	.	.	PUNCT
dpc-2847	62	1	pmid	pmid	NOUN
dpc-2847	62	2	:	:	PUNCT
dpc-2847	62	3	21944842	21944842	NUM
dpc-2847	62	4	.	.	PUNCT
dpc-2847	63	1	5	5	X
dpc-2847	63	2	.	.	X
dpc-2847	63	3	liang	liang	PROPN
dpc-2847	63	4	cp	cp	PROPN
dpc-2847	63	5	,	,	PUNCT
dpc-2847	63	6	yang	yang	PROPN
dpc-2847	63	7	cs	cs	PROPN
dpc-2847	63	8	,	,	PUNCT
dpc-2847	63	9	shen	shen	PROPN
dpc-2847	63	10	jl	jl	PROPN
dpc-2847	63	11	,	,	PUNCT
dpc-2847	63	12	chen	chen	PROPN
dpc-2847	63	13	yj	yj	PROPN
dpc-2847	63	14	.	.	PROPN
dpc-2847	63	15	sorafenib	sorafenib	PROPN
dpc-2847	63	16	-	-	PUNCT
dpc-2847	63	17	induced	induce	VERB
dpc-2847	63	18	acute	acute	NOUN
dpc-2847	63	19	localized	localize	VERB
dpc-2847	63	20	exanthematous	exanthematous	ADJ
dpc-2847	63	21	pustulosis	pustulosis	NOUN
dpc-2847	63	22	in	in	ADP
dpc-2847	63	23	a	a	DET
dpc-2847	63	24	patient	patient	NOUN
dpc-2847	63	25	with	with	ADP
dpc-2847	63	26	hepatocellular	hepatocellular	ADJ
dpc-2847	63	27	carcinoma	carcinoma	NOUN
dpc-2847	63	28	.	.	PUNCT
dpc-2847	64	1	br	br	PROPN
dpc-2847	64	2	j	j	PROPN
dpc-2847	64	3	dermatol	dermatol	NOUN
dpc-2847	64	4	.	.	PUNCT
dpc-2847	65	1	2011;165(2):443	2011;165(2):443	NUM
dpc-2847	65	2	-	-	SYM
dpc-2847	65	3	445	445	NUM
dpc-2847	65	4	.	.	PUNCT
dpc-2847	66	1	doi	doi	NOUN
dpc-2847	66	2	:	:	PUNCT
dpc-2847	66	3	10.1111	10.1111	NUM
dpc-2847	66	4	/	/	SYM
dpc-2847	66	5	j.1365	j.1365	NOUN
dpc-2847	66	6	-	-	PUNCT
dpc-2847	66	7	2133.2011.10377.x	2133.2011.10377.x	NOUN
dpc-2847	66	8	.	.	PUNCT
dpc-2847	67	1	pmid	pmid	NOUN
dpc-2847	67	2	:	:	PUNCT
dpc-2847	67	3	21495998	21495998	NUM
dpc-2847	67	4	.	.	PUNCT
dpc-2847	68	1	6	6	X
dpc-2847	68	2	.	.	X
dpc-2847	68	3	pretel	pretel	PROPN
dpc-2847	68	4	m	m	PROPN
dpc-2847	68	5	,	,	PUNCT
dpc-2847	68	6	iñarrairaegui	iñarrairaegui	PROPN
dpc-2847	68	7	m	m	PROPN
dpc-2847	68	8	,	,	PUNCT
dpc-2847	68	9	lera	lera	PROPN
dpc-2847	68	10	jm	jm	PROPN
dpc-2847	68	11	,	,	PUNCT
dpc-2847	68	12	aguado	aguado	PROPN
dpc-2847	68	13	l	l	PROPN
dpc-2847	68	14	,	,	PUNCT
dpc-2847	68	15	idoate	idoate	PROPN
dpc-2847	68	16	ma	ma	PROPN
dpc-2847	68	17	.	.	PROPN
dpc-2847	68	18	acute	acute	PROPN
dpc-2847	68	19	generalized	generalize	VERB
dpc-2847	68	20	exanthematous	exanthematous	ADJ
dpc-2847	68	21	pustulosis	pustulosis	NOUN
dpc-2847	68	22	induced	induce	VERB
dpc-2847	68	23	by	by	ADP
dpc-2847	68	24	sorafenib	sorafenib	NOUN
dpc-2847	68	25	.	.	PUNCT
dpc-2847	69	1	jama	jama	PROPN
dpc-2847	69	2	dermatol	dermatol	NOUN
dpc-2847	69	3	.	.	PUNCT
dpc-2847	70	1	2014;150(6):664	2014;150(6):664	NUM
dpc-2847	70	2	-	-	SYM
dpc-2847	70	3	666	666	NUM
dpc-2847	70	4	.	.	PUNCT
dpc-2847	70	5	doi	doi	NOUN
dpc-2847	70	6	:	:	PUNCT
dpc-2847	70	7	10.1001	10.1001	NUM
dpc-2847	70	8	/	/	SYM
dpc-2847	70	9	jamadermatol.2013.6924	jamadermatol.2013.6924	PROPN
dpc-2847	70	10	.	.	PUNCT
dpc-2847	71	1	pmid	pmid	NOUN
dpc-2847	71	2	:	:	PUNCT
dpc-2847	71	3	24671701	24671701	NUM
dpc-2847	71	4	.	.	PUNCT
dpc-2847	72	1	7	7	X
dpc-2847	72	2	.	.	X
dpc-2847	72	3	alegre	alegre	NOUN
dpc-2847	72	4	-	-	PUNCT
dpc-2847	72	5	sánchez	sánchez	NOUN
dpc-2847	72	6	a	a	PRON
dpc-2847	72	7	,	,	PUNCT
dpc-2847	72	8	de	de	X
dpc-2847	72	9	perosanz	perosanz	NOUN
dpc-2847	72	10	-	-	PUNCT
dpc-2847	72	11	lobo	lobo	NOUN
dpc-2847	72	12	d	d	NOUN
dpc-2847	72	13	,	,	PUNCT
dpc-2847	72	14	pinilla	pinilla	NOUN
dpc-2847	72	15	-	-	PUNCT
dpc-2847	72	16	pagnon	pagnon	NOUN
dpc-2847	72	17	i	i	PRON
dpc-2847	72	18	,	,	PUNCT
dpc-2847	72	19	muñozzato	muñozzato	PROPN
dpc-2847	72	20	e.	e.	PROPN
dpc-2847	72	21	sorafenib	sorafenib	PROPN
dpc-2847	72	22	-	-	PUNCT
dpc-2847	72	23	induced	induce	VERB
dpc-2847	72	24	acute	acute	NOUN
dpc-2847	72	25	generalized	generalize	VERB
dpc-2847	72	26	exanthematous	exanthematous	ADJ
dpc-2847	72	27	pustulosis	pustulosis	NOUN
dpc-2847	72	28	:	:	PUNCT
dpc-2847	72	29	an	an	DET
dpc-2847	72	30	increasing	increase	VERB
dpc-2847	72	31	association	association	NOUN
dpc-2847	72	32	?	?	PUNCT
dpc-2847	73	1	actas	actas	NOUN
dpc-2847	73	2	dermosifiliogr	dermosifiliogr	NOUN
dpc-2847	73	3	.	.	PUNCT
dpc-2847	74	1	2017;108(6):599	2017;108(6):599	X
dpc-2847	74	2	-	-	SYM
dpc-2847	74	3	601	601	NUM
dpc-2847	74	4	.	.	PUNCT
dpc-2847	75	1	doi	doi	NOUN
dpc-2847	75	2	:	:	PUNCT
dpc-2847	75	3	10.1016	10.1016	NUM
dpc-2847	75	4	/	/	SYM
dpc-2847	75	5	j.ad.2016.11.018	j.ad.2016.11.018	PROPN
dpc-2847	75	6	.	.	PUNCT
dpc-2847	76	1	pmid	pmid	NOUN
dpc-2847	76	2	:	:	PUNCT
dpc-2847	76	3	28262110	28262110	NUM
dpc-2847	76	4	.	.	PUNCT
dpc-2847	77	1	figure	figure	NOUN
dpc-2847	77	2	3	3	NUM
dpc-2847	77	3	.	.	PUNCT
dpc-2847	78	1	naranjo	naranjo	PROPN
dpc-2847	78	2	adverse	adverse	ADJ
dpc-2847	78	3	drug	drug	NOUN
dpc-2847	78	4	reaction	reaction	NOUN
dpc-2847	78	5	probability	probability	NOUN
dpc-2847	78	6	scale	scale	NOUN
dpc-2847	78	7	.	.	PUNCT
dpc-2847	79	1	#	#	NOUN
dpc-2847	79	2	naranjo	naranjo	PROPN
dpc-2847	79	3	questions	question	NOUN
dpc-2847	80	1	yes	yes	INTJ
dpc-2847	80	2	no	no	INTJ
dpc-2847	80	3	do	do	AUX
dpc-2847	80	4	not	not	PART
dpc-2847	80	5	know	know	VERB
dpc-2847	80	6	1	1	NUM
dpc-2847	80	7	.	.	PUNCT
dpc-2847	80	8	are	be	AUX
dpc-2847	80	9	there	there	PRON
dpc-2847	80	10	previous	previous	ADJ
dpc-2847	80	11	conclusive	conclusive	ADJ
dpc-2847	80	12	reports	report	NOUN
dpc-2847	80	13	on	on	ADP
dpc-2847	80	14	this	this	DET
dpc-2847	80	15	reaction	reaction	NOUN
dpc-2847	80	16	?	?	PUNCT
dpc-2847	81	1	1	1	NUM
dpc-2847	81	2	0	0	NUM
dpc-2847	81	3	0	0	NUM
dpc-2847	81	4	2	2	NUM
dpc-2847	81	5	.	.	PUNCT
dpc-2847	82	1	did	do	AUX
dpc-2847	82	2	the	the	DET
dpc-2847	82	3	adverse	adverse	ADJ
dpc-2847	82	4	event	event	NOUN
dpc-2847	82	5	occur	occur	VERB
dpc-2847	82	6	after	after	SCONJ
dpc-2847	82	7	the	the	DET
dpc-2847	82	8	suspected	suspect	VERB
dpc-2847	82	9	drug	drug	NOUN
dpc-2847	82	10	was	be	AUX
dpc-2847	82	11	administered	administer	VERB
dpc-2847	82	12	?	?	PUNCT
dpc-2847	83	1	2	2	NUM
dpc-2847	83	2	-1	-1	SYM
dpc-2847	83	3	0	0	NUM
dpc-2847	83	4	3	3	X
dpc-2847	83	5	.	.	PUNCT
dpc-2847	83	6	did	do	AUX
dpc-2847	83	7	the	the	DET
dpc-2847	83	8	adverse	adverse	ADJ
dpc-2847	83	9	reaction	reaction	NOUN
dpc-2847	83	10	improve	improve	VERB
dpc-2847	83	11	when	when	SCONJ
dpc-2847	83	12	the	the	DET
dpc-2847	83	13	drug	drug	NOUN
dpc-2847	83	14	was	be	AUX
dpc-2847	83	15	discontinued	discontinue	VERB
dpc-2847	83	16	or	or	CCONJ
dpc-2847	83	17	a	a	DET
dpc-2847	83	18	specific	specific	ADJ
dpc-2847	83	19	antagonist	antagonist	NOUN
dpc-2847	83	20	was	be	AUX
dpc-2847	83	21	administered	administer	VERB
dpc-2847	83	22	?	?	PUNCT
dpc-2847	84	1	1	1	NUM
dpc-2847	84	2	0	0	NUM
dpc-2847	84	3	0	0	NUM
dpc-2847	84	4	4	4	NUM
dpc-2847	84	5	.	.	PUNCT
dpc-2847	85	1	did	do	VERB
dpc-2847	85	2	the	the	DET
dpc-2847	85	3	adverse	adverse	ADJ
dpc-2847	85	4	reaction	reaction	NOUN
dpc-2847	85	5	reappear	reappear	NOUN
dpc-2847	85	6	when	when	SCONJ
dpc-2847	85	7	the	the	DET
dpc-2847	85	8	drug	drug	NOUN
dpc-2847	85	9	was	be	AUX
dpc-2847	85	10	readministered	readministere	VERB
dpc-2847	85	11	?	?	PUNCT
dpc-2847	86	1	2	2	NUM
dpc-2847	86	2	-1	-1	SYM
dpc-2847	86	3	0	0	NUM
dpc-2847	86	4	5	5	NUM
dpc-2847	86	5	.	.	PUNCT
dpc-2847	86	6	are	be	AUX
dpc-2847	86	7	there	there	PRON
dpc-2847	86	8	alternative	alternative	ADJ
dpc-2847	86	9	causes	cause	NOUN
dpc-2847	86	10	(	(	PUNCT
dpc-2847	86	11	other	other	ADJ
dpc-2847	86	12	than	than	ADP
dpc-2847	86	13	the	the	DET
dpc-2847	86	14	drug	drug	NOUN
dpc-2847	86	15	)	)	PUNCT
dpc-2847	86	16	that	that	PRON
dpc-2847	86	17	could	could	AUX
dpc-2847	86	18	have	have	VERB
dpc-2847	86	19	on	on	ADP
dpc-2847	86	20	their	their	PRON
dpc-2847	86	21	own	own	ADJ
dpc-2847	86	22	cause	cause	NOUN
dpc-2847	86	23	the	the	DET
dpc-2847	86	24	reaction	reaction	NOUN
dpc-2847	86	25	?	?	PUNCT
dpc-2847	87	1	-1	-1	PUNCT
dpc-2847	88	1	2	2	NUM
dpc-2847	88	2	0	0	NUM
dpc-2847	88	3	6	6	NUM
dpc-2847	88	4	.	.	PUNCT
dpc-2847	89	1	did	do	AUX
dpc-2847	89	2	the	the	DET
dpc-2847	89	3	reaction	reaction	NOUN
dpc-2847	89	4	reappear	reappear	VERB
dpc-2847	89	5	when	when	SCONJ
dpc-2847	89	6	a	a	DET
dpc-2847	89	7	placebo	placebo	NOUN
dpc-2847	89	8	was	be	AUX
dpc-2847	89	9	given	give	VERB
dpc-2847	89	10	?	?	PUNCT
dpc-2847	90	1	-1	-1	ADP
dpc-2847	90	2	1	1	NUM
dpc-2847	90	3	0	0	NUM
dpc-2847	90	4	7	7	NUM
dpc-2847	90	5	.	.	PUNCT
dpc-2847	90	6	was	be	AUX
dpc-2847	90	7	the	the	DET
dpc-2847	90	8	drug	drug	NOUN
dpc-2847	90	9	detected	detect	VERB
dpc-2847	90	10	in	in	ADP
dpc-2847	90	11	the	the	DET
dpc-2847	90	12	blood	blood	NOUN
dpc-2847	90	13	(	(	PUNCT
dpc-2847	90	14	or	or	CCONJ
dpc-2847	90	15	other	other	ADJ
dpc-2847	90	16	fluids	fluid	NOUN
dpc-2847	90	17	)	)	PUNCT
dpc-2847	90	18	in	in	ADP
dpc-2847	90	19	concentrations	concentration	NOUN
dpc-2847	90	20	known	know	VERB
dpc-2847	90	21	to	to	PART
dpc-2847	90	22	be	be	AUX
dpc-2847	90	23	toxic	toxic	ADJ
dpc-2847	90	24	?	?	PUNCT
dpc-2847	91	1	1	1	NUM
dpc-2847	91	2	0	0	NUM
dpc-2847	91	3	0	0	NUM
dpc-2847	91	4	8	8	NUM
dpc-2847	91	5	.	.	PUNCT
dpc-2847	91	6	was	be	AUX
dpc-2847	91	7	the	the	DET
dpc-2847	91	8	reaction	reaction	NOUN
dpc-2847	91	9	more	more	ADV
dpc-2847	91	10	severe	severe	ADJ
dpc-2847	91	11	when	when	SCONJ
dpc-2847	91	12	the	the	DET
dpc-2847	91	13	does	do	AUX
dpc-2847	91	14	was	be	AUX
dpc-2847	91	15	increased	increase	VERB
dpc-2847	91	16	or	or	CCONJ
dpc-2847	91	17	less	less	ADV
dpc-2847	91	18	severe	severe	ADJ
dpc-2847	91	19	when	when	SCONJ
dpc-2847	91	20	the	the	DET
dpc-2847	91	21	dose	dose	NOUN
dpc-2847	91	22	was	be	AUX
dpc-2847	91	23	decreased	decrease	VERB
dpc-2847	91	24	?	?	PUNCT
dpc-2847	92	1	1	1	NUM
dpc-2847	92	2	0	0	NUM
dpc-2847	92	3	0	0	NUM
dpc-2847	92	4	9	9	NUM
dpc-2847	92	5	.	.	PUNCT
dpc-2847	93	1	did	do	AUX
dpc-2847	93	2	the	the	DET
dpc-2847	93	3	patient	patient	NOUN
dpc-2847	93	4	have	have	VERB
dpc-2847	93	5	a	a	DET
dpc-2847	93	6	similar	similar	ADJ
dpc-2847	93	7	reaction	reaction	NOUN
dpc-2847	93	8	to	to	ADP
dpc-2847	93	9	the	the	DET
dpc-2847	93	10	same	same	ADJ
dpc-2847	93	11	or	or	CCONJ
dpc-2847	93	12	similar	similar	ADJ
dpc-2847	93	13	drugs	drug	NOUN
dpc-2847	93	14	in	in	ADP
dpc-2847	93	15	any	any	DET
dpc-2847	93	16	previous	previous	ADJ
dpc-2847	93	17	exposure	exposure	NOUN
dpc-2847	93	18	?	?	PUNCT
dpc-2847	94	1	1	1	NUM
dpc-2847	94	2	0	0	NUM
dpc-2847	94	3	0	0	NUM
dpc-2847	94	4	10	10	NUM
dpc-2847	94	5	.	.	PUNCT
dpc-2847	95	1	was	be	AUX
dpc-2847	95	2	the	the	DET
dpc-2847	95	3	adverse	adverse	ADJ
dpc-2847	95	4	event	event	NOUN
dpc-2847	95	5	confirmed	confirm	VERB
dpc-2847	95	6	by	by	ADP
dpc-2847	95	7	any	any	DET
dpc-2847	95	8	objective	objective	ADJ
dpc-2847	95	9	evidence	evidence	NOUN
dpc-2847	95	10	?	?	PUNCT
dpc-2847	96	1	1	1	NUM
dpc-2847	96	2	0	0	NUM
dpc-2847	96	3	0	0	NUM